ILMN | Rally Across the S&P 500 a Positive for Fundraising & Likely Positive for Illumina Customers

Overview

20 years after the first human genome was sequenced (almost sequenced), genetic testing appears to be entering clinical practice at an accelerating rate.   Beyond the product launch maturation and deceleration, 2019 was a difficult year for ILMN and included a substantial guidance reduction.   In addition to the headwinds ILMN cited, we believe other headwinds are reversing, including private equity and venture, NIH funding, and some restrictive changes to managed care payments and access.  Heading into 2020 we are seeing improvements that should be positive for ILMN’s revenue and sequencing consumable growth.

Thomas Tobin
Managing Director


Twitter
LinkedIn

Emily Evans
Managing Director – Health Policy



Twitter
LinkedIn